Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 312 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 3TC Clear all

Conditions: HIV Infections
Interventions: Ritonavir, Nelfinavir mesylate, Saquinavir, Delavirdine mesylate, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years and older
Enrollment: 825 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 97
States / cities: Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Diphenhydramine hydrochloride, Lymphocytes, Activated, Lamivudine, Zidovudine, Acetaminophen, Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions: abacavir/lamivudine, abacavir, lamivudine; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 52
States / cities: Phoenix, Arizona • Fountain Valley, California • Long Beach, California + 34 more

Conditions: HIV Infections
Interventions: Ritonavir, Abacavir sulfate, Amprenavir, Efavirenz, Lamivudine, Stavudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: HIV Infections
Interventions: Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 631 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 25
States / cities: Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more

Conditions: HIV Infections
Interventions: Lamivudine, Stavudine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 31
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 21 more

Conditions: HIV Infections
Interventions: Abacavir sulfate, Lamivudine and Zidovudine, Lamivudine/Zidovudine, Abacavir sulfate, Efavirenz; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 5
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Manhasset, New York + 2 more

Conditions: HIV Infections
Interventions: 3TC and FTC; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: San Jose, California

Conditions: Pediatric Immuno-Tolerant Chronic Hepatitis B
Interventions: Entecavir, Lamivudine, Pegylated Interferon Alfa-2A; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 3
States / cities: Kansas City, Missouri • New York, New York • Philadelphia, Pennsylvania

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: COBI, DRV, NRTIs; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 48
States / cities: Phoenix, Arizona • Long Beach, California • Los Angeles, California + 39 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 1,750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1997
U.S. locations: 85
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 43 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Delavirdine mesylate, Lamivudine, Zidovudine; Drug
Lead sponsor: Pharmacia and Upjohn; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Peapack, New Jersey

Conditions: HIV Infections
Interventions: Lopinavir/ritonavir, Efavirenz, Stavudine, Zidovudine, Lamivudine, Tenofovir disoproxil fumarate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 775 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 59
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 34 more

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine, Capravirine, Nelfinavir mesylate; Drug
Lead sponsor: Agouron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 9
States / cities: Clearwater, Florida • Fort Lauderdale, Florida • Miami, Florida + 6 more

Conditions: Chronic Hepatitis B
Interventions: Placebo (PLB), Adefovir Dipivoxil (ADV), Lamivudine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections, Pregnancy
Interventions: Indinavir sulfate, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 4
States / cities: San Francisco, California • Boston, Massachusetts • The Bronx, New York

Conditions: HIV-1-infection
Interventions: Bavtavirine, B/F/TAF, Standard of Care (Substudy 01), GS-1720, Standard of Care (Substudy 02), GS-6212, Standard of Care (Substudy 03); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 38
States / cities: Long Beach, California • Los Angeles, California • San Francisco, California + 14 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Abacavir sulfate, Nelfinavir mesylate, Efavirenz, Nevirapine, Lamivudine, Stavudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 1,710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 17
States / cities: San Francisco, California • Denver, Colorado • New Haven, Connecticut + 13 more

Conditions: HIV Infections
Interventions: Nelfinavir mesylate, Efavirenz, Lamivudine, Keyhole-Limpet Hemocyanin, Stavudine, Zidovudine, Didanosine; Drug
Lead sponsor: Agouron Pharmaceuticals; Industry
Eligibility: 0 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: San Diego, California

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine, Lamivudine, Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Beverly Hills, California • Los Angeles, California • Chapel Hill, North Carolina + 3 more

Conditions: HIV Infections
Interventions: Ritonavir, Nelfinavir mesylate, Nevirapine, Lamivudine, Stavudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 4 Months to 17 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 53
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 32 more

Conditions: HIV, HIV Infections
Interventions: DTG/3TC; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 50 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 24
States / cities: Phoenix, Arizona • Bakersfield, California • Palm Springs, California + 21 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine/Zidovudine, Hepatitis A Vaccine (Inactivated), Interleukin-12, Nevirapine, Stavudine, Sargramostim; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 3
States / cities: San Diego, California • Aurora, Colorado • Indianapolis, Indiana

Conditions: Hiv, HIV-1-infection, HIV Infections
Interventions: DTG/3TC versus BIC/F/TAF; Drug
Lead sponsor: Midway Specialty Care Center; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: West Palm Beach, Florida

Search by objective public record fields.

A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients

Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection

A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients

Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine

A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults

The Switch Study: The Role of Lamivudine/Emtricitabine (3TC/FTC) in Antiretroviral Regimens

A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase

Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months

A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients

Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients

Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients

Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B

A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants

Study of Novel Antiretrovirals in Participants With HIV-1

A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)

Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

A Study of Two Anti-HIV Drug Combinations

Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens

A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients

Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States